Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. Its lead development candidate, ivonescimab, is a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and is also in Phase III clinical trials for the treatment of non-small lung cancer. The company has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. Summit Therapeutics Inc. was founded in 2003 and is headquartered in Miami, Florida.

Summit Therapeutics Inc.

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Summit Therapeutics yesterday and set a price target of $30.00. The company’s shares cl...

Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

In a report released today, Etzer Darout from Barclays maintained a Hold rating on Summit Therapeutics, with a price target of $18.00. According to...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SMMT	$18.78	-2.32%	1.45M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SMMT	$18.78	-2.3%	1.45M
3
4
5
6

SMMT

SMMT

Dividend Overview

Get Summit Therapeutics Inc. Data in Excel

Get Summit Therapeutics Inc. Data in Excel